Brief: Rubius Therapeutics Announces Dosing Of First Patient In Phase 1/2 Trial Of RTX-224 For The Treatment Of Certain Solid Tumors
13/01/2022 13:04
Jan 13 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN
PHASE
1/2 TRIAL OF RTX-224, A BROAD IMMUNE AGONIST, FOR THE TREATMENT
OF CERTAIN SOLID TUMORS
Source text for Eikon: ID:nGNX5BCCsW
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft